Related Experiment Video
Updated: Dec 9, 2025

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
Proteolysis-targeting chimeras mediate the degradation of bromodomain and extra-terminal domain proteins
Yifei Yang1, Zhenwei Wu2, Pan Chen1
1Department of Medicinal Chemistry, China Pharmaceutical University, Tongjia Xiang 24, Nanjing, 210009, PR China.
Abstract:
Bromodomain and extra-terminal domain (BET) protein family plays an important role in regulating gene transcription preferentially at super-enhancer regions and has been involved with several types of cancers as a candidate. Up to now, there are 16 pan-BET inhibitors in clinical trials, however, most of them have undesirable off-target and side-effects. The proteolysis-targeting chimeras technology through a heterobifunctional molecule to link the target protein and E3 ubiquitin ligase, causes the target's ubiquitination and subsequent degradation. By using this technology, the heterobifunctional small-molecule BET degraders can induce BET protein degradation. In this review, we discuss the advances in the drug discovery and development of BET-targeting proteolysis-targeting chimeras.
Insights
Proteolysis-targeting chimeras offer a novel approach to degrade Bromodomain and extra-terminal domain (BET) proteins, addressing limitations of current inhibitors. This technology promises targeted cancer therapy with potentially fewer side effects.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Bromodomain and extra-terminal domain (BET) proteins regulate gene transcription and are implicated in various cancers.
- Current pan-BET inhibitors in clinical trials exhibit off-target effects and undesirable side effects.
- Proteolysis-targeting chimeras (PROTACs) offer a new therapeutic strategy by inducing target protein degradation.
Purpose of the Study:
- To review advances in the development of BET-targeting proteolysis-targeting chimeras.
- To highlight the potential of PROTAC technology for cancer treatment.
- To discuss the advantages of BET degraders over traditional inhibitors.
Main Methods:
- Review of current literature on BET protein family.
- Analysis of proteolysis-targeting chimeras technology and its application to BET proteins.
- Discussion of drug discovery and development strategies for BET degraders.
Main Results:
- BET protein family is a promising target for cancer therapy.
- Proteolysis-targeting chimeras technology enables targeted degradation of BET proteins.
- Heterobifunctional small molecules can induce BET protein ubiquitination and degradation.
Conclusions:
- BET-targeting proteolysis-targeting chimeras represent a significant advancement in cancer drug discovery.
- This technology offers a potential solution to the limitations of existing BET inhibitors.
- Further development of BET degraders holds promise for more effective and safer cancer therapies.
Related Concept Videos
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Restarting Stalled Replication Forks
Export of Misfolded Proteins out of the ER
Caspases

